ES2063296T3 - Procedimiento para fabricar comprimidos que contienen naproxeno o naproxeno sodico secado por aspersion. - Google Patents

Procedimiento para fabricar comprimidos que contienen naproxeno o naproxeno sodico secado por aspersion.

Info

Publication number
ES2063296T3
ES2063296T3 ES90314164T ES90314164T ES2063296T3 ES 2063296 T3 ES2063296 T3 ES 2063296T3 ES 90314164 T ES90314164 T ES 90314164T ES 90314164 T ES90314164 T ES 90314164T ES 2063296 T3 ES2063296 T3 ES 2063296T3
Authority
ES
Spain
Prior art keywords
tablets
naproxeno
spray
dry powder
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90314164T
Other languages
English (en)
Inventor
Roy Kuramoto
Randal Owen Pendleton
Zadauddin Tanwir Chowhan
Hafez Hafezzadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex Pharmaceuticals International Ltd
Original Assignee
Syntex Pharmaceuticals International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Pharmaceuticals International Ltd filed Critical Syntex Pharmaceuticals International Ltd
Application granted granted Critical
Publication of ES2063296T3 publication Critical patent/ES2063296T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBE LA PREPARACION DE COMPOSICIONES FARMACEUTICAS EN POLVO QUE SE PUEDAN COMPRIMIR DIRECTAMENTE EN TABLETAS. EL PROCESO DESCRITO INCLUYE EL SOMETER UNA SUSPENSION O DISOLUCION ACUOSA DE UN MEDICAMENTO ACTIVO FARMACEUTICAMENTE, ESPECIFICAMENTE NAPROXEN O NAPROXEN DE SODIO (QUE EN SUSPENSION PUEDE OBTENERSE DIRECTAMENTE SIN SECAR A PARTIR DE LA SINTESIS DEL MEDICAMENTO), SOLO O MEZCLADO CON UNA MEZCLA ACUOSA DE MATERIALES EXCIPIENTES, A UNA FORMA CONTROLADA DE SECADO POR PULVERIZACION PARA PRODUCIR UN POLVO SECO CON PARTICULAS DE TAMAÑO UNIFORME EN LA QUE EL MEDICAMENTO SE DISPERSA UNIFORMEMENTE Y SE CUBRE CON LOS EXCIPIENTES. EL POLVO PUEDE COMBINARSE FACILMENTE CON MATERIALES EXCIPIENTES SECOS ADICIONALES Y FORMARSE EN TABLETAS. EL PROCESO FACILITA AHORROS SUSTANCIALES EN LA FABRICACION DE LAS TABLETAS. LOS COMPUESTOS EN POLVO SECO POR PULVERIZACION SON ALTAMENTE COMPRIMIBLES. UTILIZANDO ESTOS COMPUESTOS EN POLVO SECO POR PULVERIZACION, LAS TABLETAS FORMADAS SE DISUELVEN FACILMENTEY TAMBIEN SON ESTABLES EN CONDICIONES NORMALES DE ALMACENAMIENTO Y CONDICIONES SEVERAS DE TEMPERATURA Y HUMEDAD RELATIVA.
ES90314164T 1989-12-22 1990-12-21 Procedimiento para fabricar comprimidos que contienen naproxeno o naproxeno sodico secado por aspersion. Expired - Lifetime ES2063296T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45510989A 1989-12-22 1989-12-22

Publications (1)

Publication Number Publication Date
ES2063296T3 true ES2063296T3 (es) 1995-01-01

Family

ID=23807439

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90314164T Expired - Lifetime ES2063296T3 (es) 1989-12-22 1990-12-21 Procedimiento para fabricar comprimidos que contienen naproxeno o naproxeno sodico secado por aspersion.

Country Status (16)

Country Link
EP (1) EP0436373B1 (es)
JP (1) JPH05320045A (es)
KR (1) KR910011241A (es)
AT (1) ATE110267T1 (es)
AU (1) AU640725B2 (es)
CA (1) CA2032956A1 (es)
DE (1) DE69011836T2 (es)
ES (1) ES2063296T3 (es)
FI (1) FI906372L (es)
HU (1) HUT59594A (es)
IE (1) IE904666A1 (es)
IL (1) IL96749A0 (es)
NO (1) NO905557L (es)
NZ (1) NZ236631A (es)
PT (1) PT96229B (es)
ZA (1) ZA9010353B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0636023B1 (en) * 1992-04-15 1999-08-11 Alteon, Inc. Aminoguanidine spray drying process
AU5135898A (en) * 1996-12-03 1998-06-29 Schering-Plough Kabushiki Kaisha Controlled release matrix tablet and method for its preparation
RU2191577C1 (ru) * 2001-04-19 2002-10-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая противовоспалительная композиция и способ ее получения
EP1411986B1 (en) * 2001-07-30 2008-03-12 DSM IP Assets B.V. Composition comprising epigallocatechin gallate
ES2878403T3 (es) 2002-02-01 2021-11-18 Bend Res Inc Método para preparar dispersiones de fármacos amorfas sólidas homogéneas secadas mediante pulverización utilizando aparatos de secado por pulverización modificados
US7704528B2 (en) * 2003-05-05 2010-04-27 Isp Investments Inc. Binder composition and method for processing poorly compressible drugs into tablets of predetermined hardness and friability
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
PE20050445A1 (es) * 2003-10-30 2005-06-18 Bayer Consumer Care Ag Forma de presentacion del naproxeno sodico
JP2008222567A (ja) * 2007-03-08 2008-09-25 Iwate Univ 微粒子の製造方法
TW201113266A (en) * 2009-09-02 2011-04-16 Ziopharm Oncology Inc Pharmaceutical formulations for indibulin
IE20100799A1 (en) * 2010-12-22 2012-08-01 Eurand Pharmaceuticals Ltd Pharmaceutical composites of poorly water soluble drugs and polymers
US20190105274A1 (en) * 2015-07-13 2019-04-11 Kyowa Hakko Bio Co., Ltd. Tablets containing arginine at high concentration
JP6619644B2 (ja) * 2015-12-22 2019-12-11 アサヒグループ食品株式会社 錠剤の製造方法、及び錠剤原料用顆粒の製造方法
JP7163015B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 経口固形組成物
BR112022003419A2 (pt) * 2019-08-26 2022-05-24 Dsm Ip Assets Bv Forma de dosagem oral sólida compreendendo naproxeno e vitamina b12

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744987A (en) * 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
EP0298666B1 (en) * 1987-07-08 1993-08-11 American Home Products Corporation Spray dried ibuprofen compositions
IT1226549B (it) * 1988-07-12 1991-01-24 Resa Farma Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.

Also Published As

Publication number Publication date
EP0436373B1 (en) 1994-08-24
AU640725B2 (en) 1993-09-02
CA2032956A1 (en) 1991-06-23
NO905557L (no) 1991-06-24
FI906372A7 (fi) 1991-06-23
HUT59594A (en) 1992-06-29
FI906372A0 (fi) 1990-12-21
NO905557D0 (no) 1990-12-21
NZ236631A (en) 1993-03-26
ATE110267T1 (de) 1994-09-15
PT96229B (pt) 1998-06-30
ZA9010353B (en) 1992-08-26
DE69011836D1 (de) 1994-09-29
IL96749A0 (en) 1991-09-16
PT96229A (pt) 1991-09-30
FI906372L (fi) 1991-06-23
IE904666A1 (en) 1991-07-17
JPH05320045A (ja) 1993-12-03
DE69011836T2 (de) 1995-03-09
KR910011241A (ko) 1991-08-07
AU6837590A (en) 1991-06-27
EP0436373A1 (en) 1991-07-10
HU908395D0 (en) 1991-07-29

Similar Documents

Publication Publication Date Title
ES2063296T3 (es) Procedimiento para fabricar comprimidos que contienen naproxeno o naproxeno sodico secado por aspersion.
KR880004805A (ko) 분무건조된 아세트아미노펜
UY23804A1 (es) Procedimiento de preparacion de medicamentos en forma de comprimidos con liberacion retardada de sustancia activa.
CO4560546A1 (es) Formulacion con granulacion en humedo de acidos bisfosfonicos
ES2081349T3 (es) Rotogranulaciones y recubrimientos para enmascarar el sabor para la preparacion de comprimidos farmaceuticos de mascar.
KR910014120A (ko) 피모벤단의 경구용 약제학적 제제
KR880012213A (ko) 이부프로펜 서방형 매트릭스 및 이의 제조방법
KR890001526A (ko) 경구용 서방성 아세트 아미노펜 제형 및 이의 제조방법
ES2086542T3 (es) Procedimiento para la fabricacion de matrices de celulosa porosas.
AR037642A1 (es) Preformulacion farmaceutica para tabletado, y procedimiento para su preparacion
ES2131318T3 (es) Pelets.
ES2029776T3 (es) Procedimiento para la preparacion de composiciones farmaceuticas que contienen bromocriptina con gran estabilidad y productos relacionados.
ES2245275T1 (es) Formulacion solida estable de sal de enalapril y procedimiento para su preparacion.
JP6168673B2 (ja) アリールアルキルアミン化合物含有医薬組成物
AR036797A1 (es) Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
RU2199312C1 (ru) Способ получения лекарственных средств из растительных экстрактов в твердой форме
AR025879A1 (es) Granulaciones de celulosa hidrolizada de sales de farmacos
AR001349A1 (es) Nueva composición farmacéutica que contiene trimebutina y proceso para su preparación.
RU2012124704A (ru) Лекарственное средство на основе сухих экстрактов лекарственных растений и способ его получения (варианты)
RU2361573C2 (ru) Твердая фармацевтическая композиция с содержанием солей левотироксина и/или лиотиронина
DE59201206D1 (de) Vitamin enthaltende Formulierungen und deren Herstellung.
RU98115790A (ru) Способ получения таблеток ранитидина
DE69103724D1 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren.
BR9903490A (pt) Processo para a preparação de composições farmacêuticas de liberação programada contendo nimodipine, que permitem a liberação gradual e a manuntenção da ação terapeutica
RU2023132871A (ru) Составы в фиксированных дозах

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 436373

Country of ref document: ES